Intranasal hydroxypropyl-β-cyclodextrin-adjuvanted influenza vaccine protects against sub-heterologous virus infection

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Unknown venue

• Publication date

  2016-09-23

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• A Glycolipid α-GalCer Derivative, 7DW8-5 as a Novel Mucosal Adjuvant for the Split Inactivated Influenza Vaccine

  2022cites this paper
• Nanoparticles of folic acid‐methyl‐β‐cyclodextrin (FA‐MβCD)/adamantane‐albumin exhibit enhanced antitumor activity compared with FA‐MβCD alone

  2022cites this paper
• Versatile Nasal Application of Cyclodextrins: Excipients and/or Actives?

  2021cites this paper
• Cyclodextrins in Antiviral Therapeutics and Vaccines

  2021cites this paper
• The effect of folate-appended methyl-β-cyclodextrin increases on survival rates in a peritoneal dissemination mouse models of human ovarian cancer

  2021cites this paper
• Role of Damage-Associated Molecular Pattern/Cell Death Pathways in Vaccine-Induced Immunity

  2021cites this paper
• COVID-19: A Recommendation to Examine the Effect of Mouthrinses with β-Cyclodextrin Combined with Citrox in Preventing Infection and Progression

  2020cites this paper
• Cyclodextrins based delivery systems for macro biomolecules.

  2020cites this paper
• Injectable Excipients as Novel Influenza Vaccine Adjuvants

  2019cites this paper
• DAMP-Inducing Adjuvant and PAMP Adjuvants Parallelly Enhance Protective Type-2 and Type-1 Immune Responses to Influenza Split Vaccination

  2018cites this paper